Third Arc Bio
Third Arc Bio is a biotech company developing multifunctional antibodies optimized for T cell engagement in solid tumors and inflammatory & immunology (I&I) diseases. Their drug development engine leverages two technologies—a solid tumor synergy platform and an I&I platform—to create best-in-class T cell engagement for superior efficacy and safety. This approach aims to address significant unmet needs in oncology and autoimmunity.
Buy Funded Startups lists
Funding Round: Series A
Funding Amount: $165M
Date: 23-Jul-2024
Investors: Vida Ventures, Cormorant Asset Management, Hillhouse Investment, Omega Funds, Goldman Sachs Alternatives, BVF Partners LP, T. Rowe Price Associates, Inc., Janus Henderson Investors, abrdn Inc., Marshall Wace, Foresite Capital, Logos Capital, Freepoint Capital Group, AbbVie Ventures
Markets: Biotechnology, Oncology, Immunology, Health Care, Life Science, Medical
HQ: Philadelphia, Pennsylvania, United States
Founded: 2022
Website: https://thirdarcbio.com/
LinkedIn: https://www.linkedin.com/company/third-arc-bio
Crunchbase: https://www.crunchbase.com/organization/third-arc-bio
Leave a Comment
Comments
No comments yet.